Lower exposure to bictegravir in third trimester in pregnant women living with HIV

L. van der Wekken-Pas¹, C. Hidalgo-Tenorio², J. Rockstroh³, K. van Bremen³, O. Richel¹, J. Molto⁴, J.S. Lambert⁵, D. Burger¹, A. Colbers¹

1. Radboudumc (NL), 2 Hospital Universitario Virgen de las Nieves (ES), 3 Universitätsklinikum Bonn (DE), 4 Hospital Universitari Germans Trias i Pujol (ES), 5 Saint James hospital (IE)

Introduction

Antiretroviral treatment in pregnant women living with HIV \bullet serves to reduce the risk of mother to child transmission of the

	3 rd trimester (n =8)	Postpartum (n =7)	GMR (CI90%)
AUC _{0-24,} mg*h/L (CV%)	47.3 (21.5)	94.2 (28.2)	0.50 (0.40- 0.62)
C _{max} , mg/L (CV%)	3.9 (17.0)	6.8 (21.3)	0.59 (0.48 – 0.73)
C _{trough,} mg/L (CV%)	0.9 (38.4)	2.4 (46.3)	0.38 (0.28 – 0.51)
T _{1/2} , h (CV%)	12.2 (38.7)	15.8 (33.1)	0.70 (0.53 – 0.91)

virus, but also to guarantee maternal health.

Due to physiological changes during pregnancy, drug concentrations may be altered, whereby drug efficacy might be hampered.

Objective

To compare the pharmacokinetic profile of bictegravir – an integrase inhibitor which is increasingly being used in the treatment of HIV - during the third trimester of pregnancy and in a non-pregnant state


Methods

multicentre, open-label, non-randomized this trial In (www.PANNAstudy.com) pregnant women living with HIV and using a bictegravir containing regimen were included.

Pharmacokinetic sampling (t = 0, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours) was performed in the third trimester and 4-6 weeks postpartum.

Plasma concentrations were determined with the use of LC-MSMS.

Table 1: PK parameters in 3rd trimester and postpartum. 1 subject was excluded from noncompartmental analysis of 3rd trimester values, because too many missing values. 2 women did not return for post partum assessment.



Results

Demographics Plasma concentrations of 9 women were obtained. Median (IQR) was 35 (33-34) year. All women had a suppressed viral load at delivery. Median (IQR) time post partum was 5 (4.5 -8) weeks.




Figure 2-4 AUC₀₋₂₄, $C_{max} C_{trough}$ (dotted line is PA-IC90 0.16mg/) and $T_{1/2}$ of individual patients

Safety

No mother to child transmission or congenital abnormalities were observed.

Cordblood was obtained from 3 neonates and the maternal plasma cord blood ratios were 0.65, 1.42 and 1.49 respectively.

Conclusion

Figure 1: Geometric mean and CV% of plasma concentrations of bictegravir in 3rd trimester and post partum

- Bictegravir-exposure is lower in third trimester compared to postpartum, but C_{trough} remained above the PA-IC95
- This effect can probably be attributed to increased hepatic clearance trough CYP3A4 and UGT1A1. More data are needed to confirm our findings.

